

Basic class	Established revised 1998 quotas	Basic class	Established revised 1998 quotas
Alpha-methylthiofentanyl	2	Meperidine	10,111,000
Aminorex	7	Methadone (for sale)	5,975,000
Beta-acetylmethadol	2	Methadone (for conversion)	585,000
Beta-hydroxyfentanyl	2	Methadone Intermediate	8,939,000
Beta-hydroxy-3-methylfentanyl	2	Methamphetamine (for conver-	
Beta-methadol	2	sion)	723,000
Betaprodine	2	Methylphenidate	14,442,000
Bufotenine	2	Morphine (for sale)	12,445,000
Cathinone	9	Morphine (for conversion)	77,975,000
Codeine-N-oxide	2	Nabilone	2
Diethyltryptamine	2	Noroxymorphone (for sale)	25,000
Difenoxin	16,000	Noroxymorphone (for conver-	
Dihydromorphone	7	sion)	2,117,000
Dimethyltryptamine	2	Opium	615,000
Ethylamine Analog of PCP	5	Oxycodone (for sale)	12,118,000
Heroin	2	Oxymorphone	198,000
Hydroxypethidine	2	Pentobarbital	19,501,000
Lysergic acid diethylamide		Phencyclidine	60
(LSD)	57	Phenmetrazine	2
Mescaline	7	Phenylacetone	10
Methaqualone	17	Secobarbital	397,000
Methcathinone	11	Sufentanil	1,800
Morphine-N-oxide	2	Thebaine	17,695,000
N-Ethylamphetamine	7		
N-Hydroxy-3,4-			
Methylenedioxyamphetamine	4		
N,N-Dimethylamphetamine	7		
Noracymethadol	2		
Norlevorphanol	2		
Normethadone	7		
Normorphine	7		
Para-fluorofentanyl	2		
Pholcodine	2		
Propiram	412,800		
Psilocin	2		
Psilocybin	2		
Tetrahydrocannabinols	51,000		
Thiofentanyl	2		
Trimeperidine	2		
SCHEDULE II			
1-Phenylcyclohexylamine	15		
1-			
Piperidinocyclohexanecarbo-			
nitrile (PCC)	12		
Alfentanil	8,100		
Amobarbital	12		
Amphetamine	5,554,000		
Cocaine	550,100		
Codeine (for sale)	62,020,000		
Codeine (for conversion)	23,906,000		
Desoxyephedrine	1,184,000		
1,151,000 grams of			
levodesoxyephedrine for			
use in a non-controlled,			
non-prescription product			
and 33,000 grams for			
methamphetamine.			
Dextropropoxyphene	109,500,000		
Dihydrocodeine	141,000		
Diphenoxylate	1,600,000		
Ecgonine	651,000		
Ethylmorphine	12		
Fentanyl	228,000		
Glutethimide	2		
Hydrocodone (for sale)	16,314,000		
Hydrocodone (for conversion) ..	3,000,000		
Hydromorphone	766,000		
Isomethadone	12		
Levo-alpha-acetylmethadol			
(LAAM)	356,000		
Levomethorphan	2		
Levorphanol	15,000		

beneficial. Accordingly, the Acting Deputy Administrator has determined that this action does not require a regulatory flexibility analysis.

Dated: September 3, 1998.

Donnie R. Marshall,

Acting Deputy Administrator.

[FR Doc. 98-24621 Filed 9-14-98; 8:45 am]

BILLING CODE 4410-09-M

NUCLEAR REGULATORY COMMISSION

[Docket No. 50-260 and 50-296]

Tennessee Valley Authority; Notice of Issuance of Amendment to Facility Operating License

The U.S. Nuclear Regulatory Commission (NRC, the Commission) has issued Amendment Nos. 254 and 214 to Facility Operating License Nos. DPR-52 and DPR-68 issued to the Tennessee Valley Authority (TVA or the licensee) for operation of the Browns Ferry Nuclear Plant (BFN), Units 2 and 3, respectively, located in Limestone County, Alabama.

The amendments allow operation of BFN Units 2 and 3 at 3458 Megawatts thermal and approve changes to the TS to implement uprated power operation. The application for the amendments complies with the standards and requirements of the Atomic Energy Act of 1954, as amended (the Act) and the Commission's rules and regulations. The Commission has made appropriate findings as required by the Act and the Commission's rules and regulations in 10 CFR Chapter I, which are set forth in the license amendments.

Notices of Consideration of Issuance of Amendments to facility Operating License and Opportunity for Hearing in connection with this action were published in the **Federal Register** on June 9, 1998 (63 FR 31533), and July 28, 1998 (63 FR 40323). The licensee provided additional details by letters dated March 20, May 22, June 12 and 17, and July 24 and 31, and September 1, 1998, which did not affect the staff's proposed action described in the above-cited FR notices. No request for a hearing or petition for leave to intervene was filed following these notices.

The Commission has prepared an environmental assessment of the action and has determined not to prepare an environmental impact statement. Based upon the environmental assessment, the Commission has concluded that the issuance of the amendments will not have a significant impact on the quality of the human environment (63 FR 46491).

The Acting Deputy Administrator further orders that aggregate production quotas for all other Schedules I and II controlled substances included in Sections 1308.11 and 1308.12 of Title 21 of the Code of Federal Regulations remain at zero.

The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866. This action has been analyzed in accordance with the principles and criteria contained in Executive Order 12612, and it has been determined that this matter does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment.

The Acting Deputy Administrator hereby certifies that this action will have no significant impact upon small entities whose interests must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601 et seq. The establishment of aggregate production quotas for Schedules I and II controlled substances is mandated by law and by international treaty obligations.

Aggregate production quotas apply to approximately 200 DEA registered bulk and dosage form manufacturers of Schedules I and II controlled substances. The quotas are necessary to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and the establishment and maintenance of reserve stocks. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither negative nor

For further details with respect to this action, see the application for amendments dated October 1, 1997, as supplemented October 14, 1997, March 16 and 20, April 1 and 28, May 1, 20 and 22, June 12, 17 and 26, and July 17, 24 and 31, and September 1, 1998, which are available for public inspection at the Commission's Public Document Room, the Gelman Building, 2120 L Street NW., Washington, DC and at the local public document room located at the Athens Public Library, 405 E. South Street, Athens, Alabama.

Dated at Rockville, Maryland, this 8th day of September 1998.

For the Nuclear Regulatory Commission.

Frederick J. Hebdon,

Project Director, Project Directorate II-3, Division of Reactor Projects—I/II, Office of Nuclear Reactor Regulation.

[FR Doc. 98-24717 Filed 9-14-98; 8:45 am]

BILLING CODE 7590-01-P

NUCLEAR REGULATORY COMMISSION

Advisory Committee on Reactor Safeguards, Subcommittee Meeting on Planning and Procedures Meeting

The ACRS Subcommittee on Planning and Procedures will hold a meeting on September 29, 1998, Room T-2B1, 11545 Rockville Pike, Rockville, Maryland.

The entire meeting will be open to public attendance, with the exception of a portion that may be closed pursuant to 5 U.S.C. 552b(c) (2) and (6) to discuss organizational and personnel matters that relate solely to internal personnel rules and practices of ACRS, and information the release of which would constitute a clearly unwarranted invasion of personal privacy.

The agenda for the subject meeting shall be as follows:

Tuesday, September 29, 1998—10:00 a.m.—12:00 Noon.

The Subcommittee will discuss proposed ACRS activities and related matters. It may also discuss the qualifications of candidates for appointment to the ACRS. The purpose of this meeting is to gather information, analyze relevant issues and facts, and to formulate proposed positions and actions, as appropriate, for deliberation by the full Committee.

Oral statements may be presented by members of the public with the concurrence of the Subcommittee Chairman; written statements will be accepted and made available to the Committee. Electronic recordings will be permitted only during those portions of the meeting that are open to the

public, and questions may be asked only by members of the Subcommittee, its consultants, and staff. Persons desiring to make oral statements should notify the cognizant ACRS staff person named below five days prior to the meeting, if possible, so that appropriate arrangements can be made. 2

Further information regarding topics to be discussed, the scheduling of sessions open to the public, whether the meeting has been canceled or rescheduled, the Chairman's ruling on requests for the opportunity to present oral statements, and the time allotted therefor can be obtained by contacting the cognizant ACRS staff person, Dr. John T. Larkins (telephone: 301/415-7360) between 7:30 a.m. and 4:15 p.m. (EDT). Persons planning to attend this meeting are urged to contact the above named individual one or two working days prior to the meeting to be advised of any changes in schedule, etc., that may have occurred.

Dated: September 9, 1998.

Sam Duraiswamy,

Chief, Nuclear Reactors Branch.

[FR Doc. 98-24712 Filed 9-14-98; 8:45 am]

BILLING CODE 7590-01-P

NUCLEAR REGULATORY COMMISSION

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Nuclear Regulatory Commission.

DATES: Weeks of September 14, 21, 28, and October 5, 1998.

PLACE: Commissioners' Conference Room, 11555 Rockville Pike, Rockville, Maryland.

STATUS: Public and Closed.

MATTERS TO BE CONSIDERED:

Week of September 14

Tuesday, September 15

2:00 p.m.—Briefing by Reactor Vendors Owners Groups (Public Meeting) (Contact: Bryan Sheron, 301-415-1274).

3:30 p.m.—Affirmation Session (Public Meeting).

* (Please Note: This item will be affirmed immediately following the conclusion of the preceding meeting.)

(a) Hydro Resources Inc.: Presiding Officer's Memorandum and Order Ruling on Petitions and Areas of Concern: Granting Request for Hearing; Scheduling, LBP 98-9, May 13, 1998 (Contact: Ken Hart, 301-415-1659).

Wednesday, September 16

10:00 a.m.—Briefing on Investigative Matters (Closed—Ex. 5 and 7)

Week of September 21—Tentative

There are no meetings the week of September 21.

Week of September 28—Tentative

There are no meetings the week of September 28.

Week of October 5—Tentative

Wednesday, October 7

11:30 a.m.—Affirmation Session (Public Meeting).

*The schedule for Commission meetings is subject to change on short notice. To verify the status of meetings call (Recording)—(301) 415-1292. Contact person for more information: Bill Hill (301) 415-1661.

The NRC Commission Meeting Schedule can be found on the Internet at:
<http://www.nrc.gov/SECY/smj/schedule.htm>

This notice is distributed by mail to several hundred subscribers; if you no longer wish to receive it, or would like to be added to it, please contact the Office of the Secretary, Attn: Operations Branch, Washington, D.C. 20555 (301-415-1661). In addition, distribution of this meeting notice over the Internet system is available. If you are interested in receiving this Commission meeting schedule electronically, please send an electronic message to wmh@nrc.gov or dkw@nrc.gov.

Dated: September 11, 1998.

William M. Hill, Jr.,

Secy, Tracking Officer, Office of the Secretary.

[FR Doc. 98-24834 Filed 9-11-98; 2:29 pm]

BILLING CODE 7590-01-M

PENSION BENEFIT GUARANTY CORPORATION

Interest Assumption for Determining Variable-Rate Premium; Interest Assumptions for Multiemployer Plan Valuations Following Mass Withdrawal

AGENCY: Pension Benefit Guaranty Corporation.

ACTION: Notice of interest rates and assumptions.

SUMMARY: This notice informs the public of the interest rates and assumptions to be used under certain Pension Benefit Guaranty Corporation regulations. These rates and assumptions are published elsewhere (or are derivable from rates published elsewhere), but are collected